Page 5 - Fast Track Status News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL s in Conjunction with ASH Annual Meeting

HOUSTON - Moleculin Biotech, Inc., , a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced the.

United statesSan diegoWalter klempJenene thomasDrug administrationSecurities exchangeMoleculin biotech incExchange commissionAmerican cancer societyAmerican society of hematology meetingEuropean phaseHematology meetingChief executive officerSuspect adverse reaction reportFast track statusOrphan drug designation

Moleculin Biotech (MBRX) Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML

Moleculin Biotech (MBRX) Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesWalter klempAmerican society of hematology meetingDrug administrationMoleculin biotech incExchange commissionMoleculin biotechEuropean phaseAmerican societyHematology meetingChief executive officerSuspect adverse reaction reportFast track statusOrphan drug designation

Can-Fite: Complete Response and 6 9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson Seite 1

21.11.2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that a patient who participated in the . Seite 1

Motti farbsteinDrug administrationData monitoring committeeEuropean medicines agencyCan fite phaseOrphan drugFast track statusIndependent data monitoring committeeCan fite

Anthos Therapeutics Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation

CAMBRIDGE, Mass. (BUSINESS WIRE) Nov 12, 2023

United statesUnited kingdomColl cardiolThromb haemostDan bloomfieldAnthos therapeutics incAmerican heart associationHarvard medical schoolDrug administrationProgram in cancer associated thrombosisBlackstone life sciencesBroad instituteCenters for diseasePrimary endpointClinically relevant non major bleeding comparedAtrial fibrillation

Moleculin Biotech (MBRX) presents positive Phase 1B/2 clinical trial evaluating Annamycin

Moleculin Biotech (MBRX) presents positive Phase 1B/2 clinical trial evaluating Annamycin
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Liposomal annamycinWalter klempBrian andrew vanMoleculin biotech incWashington university school of medicineDrug administrationMoleculin biotechPreviously treated soft tissue sarcomasPulmonary metastasesAndrew van tineWashington university schoolChief executive officerFast track statusOrphan drug designation